VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
This approval is significant for VERAXA as it provides the company with additional tools to finance its operations and pursue growth opportunities without the need for repeated shareholder votes. The capital band, for instance, allows the board to issue shares within a predefined range, streamlining future capital raises. The expanded board size could also bring in new expertise to guide the company through its next phase of development.
VERAXA is focused on discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s BiTAC platform is central to its pipeline, which it aims to advance into clinical development. Founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), VERAXA leverages transformative technologies to design its candidates.
The strong shareholder turnout—72.20% of outstanding shares represented—and the near-unanimous voting result (99.94% in favor) indicate confidence in management's strategy. This mandate could accelerate VERAXA's efforts in oncology pipeline development and potential partnerships. The company’s ability to now access a broader range of financing options may be critical as it moves its candidates through preclinical and clinical stages, a capital-intensive process.
For investors, the approval reduces uncertainty around the company’s governance and financing capabilities. The enhanced framework could enable VERAXA to act quickly on strategic initiatives, such as licensing deals or acquisitions, without delays from additional shareholder meetings. The move aligns with the company's commitment to building a premier engine for antibody-based therapeutics, as outlined in its corporate mission.
As VERAXA continues to develop its pipeline, the market will watch for updates on its BiTAC technology and potential clinical data. The company’s newsroom provides ongoing updates for those interested in following its progress.
